Aclaris Q4 net loss improves to $1.5M on $17.6M revenue; cash down to $181.9M

Aclaris Therapeutics, Inc.

2023-FY EPS reported -$1.27 revenue$31,249,000

Net loss $1.5M vs $27.6M YoY; revenue $17.6M vs $7.8M driven by Sun Pharma upfront payment.
Full-year net loss $88.5M; cash & securities $181.9M (Dec 2023) vs $229.8M (Dec 2022).
Impairment charge of $6.6M on IPR&D asset after discontinuing an immuno-inflammatory drug candidate.
Positive Phase 2b top-line for ATI-1777 in atopic dermatitis; seeking a partner for development/commercialization.
Co-founder Dr. Neal Walker returns as Interim CEO; company to advance zunsemetinib in oncology via Washington University trials.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aclaris Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022., net income Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N.

Period: fourth quarter and full year ended December 31, 2023
Revenue: Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022.
Net income: Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N
Result: reported results

Exact text from the filing

Aclaris Therapeutics, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2023

View on SEC.gov

Browse all earnings releases →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-001752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.